Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes novel therapies for central nervous system conditions. The company’s commercial offerings include AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness related to obstructive sleep apnea or narcolepsy, and SYMBRAVO for acute migraine treatment. Axsome also advances an investigational pipeline addressing psychiatric and neurological indications, including AXS-05 for Alzheimer’s disease agitation and smoking cessation, solriamfetol for conditions such as attention deficit hyperactivity disorder, and late-stage candidates for narcolepsy and fibromyalgia. Its products primarily serve adult patients diagnosed with these targeted medical conditions.

The company retains commercial rights within the United States and engages in licensing partnerships to market products internationally. Its commercial reach outside the U.S. includes distribution in Europe and selected territories across the Middle East and North Africa through a partner agreement. Axsome Therapeutics maintains its principal executive offices at One World Trade Center in New York, New York.

Summary of the business section of Axsome Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application.”